Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.

A recent study characterizes silent seizures in a mouse model of Dravet syndrome and identifies a new brain area that could be targeted to stop them. As early as 3 months of age, infants with a severe ...

Atypical, because they last longer--10 to 30 seconds on average--than those seen in children with typical absence epilepsy. Absence, because the patients appear as if they are mentally absent during ...

Nat Clin Pract Neurol. 2007;3(9):505-516. Myoclonic Status Epilepticus. Myoclonic SE is characterized by continuous, usually generalized, myoclonias of cortical origin. The inclusion of myoclonic SE ...

New Treatment Option for Seizures Associated with Lennox-Gastaut Syndrome WOODCLIFF LAKE, N.J., Nov. 14 /PRNewswire/ -- Eisai Corporation of North America announced today that the U.S. Food and Drug ...

BTIG initiated coverage on Bright Minds Biosciences Inc. (NASDAQ:DRUG), a clinical-stage company focused on neurological and psychiatric disorders. Investment in Bright Minds is based on the ...

Active ingredient: Rufinamide 200 mg, 400 mg; scored tabs. Indication: Adjunctive treatment of seizures in Lennox-Gastaut syndrome (LGS). Pharmacology: LGS is a seizure disorder characterized by ...

SAN FRANCISCO, CA--January 2, 2019--As early as 3 months of age, infants with a severe form of epilepsy called Dravet syndrome start having convulsive seizures, during which their arms and legs jerk ...

Despite its rarity, NCSE is found in a wide variety of situations in childhood, some of which are described in detail below. For the sake of clarity, these conditions can be grouped in three separate ...